Pharmaceutical Composition for Preventing or Treating Adverse Drug Reactions by Statin

Abstract

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

1 - 14 . (canceled) 
     
     
         15 . A method for preventing or treating a statin-induced adverse drug reaction, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of zaragozic acid. 
     
     
         16 . The method of  claim 15 , wherein the statin is any one selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, lovastatin, cerivastatin, and mevastatin. 
     
     
         17 . The method of  claim 15 , wherein the adverse drug reactions are caused by statin administration in a state in which oxysterols produced in vivo by lipopolysaccharides are abnormally increased compared to those in normal people. 
     
     
         18 . The method of  claim 17 , wherein the adverse drug reactions are caused by damage to any one or more cells selected from the group consisting of kidney tubule cells, nerve cells, and pancreatic cells. 
     
     
         19 . The method of  claim 18 , wherein the adverse drug reaction is caused by damage to kidney tubule cells. 
     
     
         20 . The method of  claim 19 , wherein a disease caused by damage to the kidney tubule cells is any one selected from the group consisting of acute renal failure, acute tubular necrosis injury, and ischemic reperfusion injury. 
     
     
         21 . The method of  claim 18 , wherein the adverse drug reaction is caused by damage to nerve cells. 
     
     
         22 . The method of  claim 21 , wherein a disease caused by the damage to nerve cells is any one selected from the group consisting of cognitive dysfunction, dementia, Parkinson's disease, Alzheimer's disease, Huntington's syndrome, stroke, and spinal nerve damage. 
     
     
         23 . The method of  claim 18 , wherein the adverse drug reaction is caused by damage to pancreatic cells. 
     
     
         24 . The method of  claim 23 , wherein a disease caused by the damage to pancreatic cells is diabetes. 
     
     
         25 . The method of  claim 17 , wherein the oxysterols produced in vivo by lipopolysaccharides are abnormally increased due to the inflammation. 
     
     
         26 . The method of  claim 15 , wherein the adverse drug reactions are damage to kidney tubule cells, nerve cells or pancreatic cells caused by statin administration in a state in which oxysterols produced in vivo by lipopolysaccharides are abnormally increased compared to those in normal people. 
     
     
         27 . The method of  claim 26 , wherein the oxysterols produced in vivo by lipopolysaccharides are abnormally increased due to inflammation. 
     
     
         28 . The method of  claim 15 , further comprising administering a pharmaceutically effective amount of statin to the subject in need thereof. 
     
     
         29 . The method of  claim 28 , further comprising administering an ezetimibe formulation, a niacin extended-release formulation, or an amlodipine formulation to the subject in need thereof.